...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Digestive Diseases and Sciences >De novo hepatocellular carcinoma in a patient with chronic hepatitis C 5 years after sustained virologic response to interferon/ribavirin therapy.
【24h】

De novo hepatocellular carcinoma in a patient with chronic hepatitis C 5 years after sustained virologic response to interferon/ribavirin therapy.

机译：在对干扰素/利巴韦林治疗产生持续病毒学应答后的5年内，在患有慢性丙型肝炎的患者中从头发生了肝细胞癌。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Screening for hepatocellular carcinoma (HCC) is an accepted component of the long-term management of patients with chronic hepatitis C and cirrhosis. Current interferon-based regimens clear hepatitis C in approximately 50% of treated patients. Clearance is associated with improvement in liver histology, stabilization of liver disease, and, possibly, reduction in risk of HCC. One result of the improvement in therapy is an increasing number of patients with advanced fibrosis or cirrhosis who will have achieved sustained virologic remission. An important clinical question is whether to screen for the development of HCC, particularly in noncirrhotic patients, after a sustained response to antiviral therapy. Herein we report a case of a hepatitis C virus (HCV)-infected patient, Metavir fibrosis stage 3, who has sustained virologic response to antiviral therapy, but developed HCC 5 years after the completion of therapy.
机译：筛查肝细胞癌（HCC）是慢性丙型肝炎和肝硬化患者长期治疗的公认组成部分。当前基于干扰素的治疗方案在大约50％的患者中清除了丙型肝炎。清除与改善肝脏组织学，稳定肝脏疾病以及可能降低HCC风险有关。改善治疗的结果之一是，将有持续的病毒学缓解的晚期纤维化或肝硬化患者数量不断增加。一个重要的临床问题是对抗病毒治疗持续反应后是否筛查HCC的发展，特别是在非肝硬化患者中。在此，我们报告了一例感染丙型肝炎病毒（HCV）的患者，即Metavir纤维化3期患者，该患者对抗病毒治疗具有持续的病毒学应答，但在治疗完成5年后发展为HCC。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号